Literature DB >> 15093603

Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property.

C Charnay1, S Bégu, C Tourné-Péteilh, L Nicole, D A Lerner, J M Devoisselle.   

Abstract

The aim of this study is to determine the feasibility of loading biologically active molecules into templated mesoporous silica (MCM 41). This material shows an important mesoporosity associated to hexagonally organized channels, a narrow pore size distribution and a large surface area. Ibuprofen was selected as a model molecule since it is a well documented and much used anti-inflammatory drug. Furthermore, it has a lipophilic character and its molecular size is suitable for inclusion within the mesopores of the MCM 41 material. In order to load ibuprofen within the mesopores, adsorption experiments using various solvents or successive impregnations with solutions of ibuprofen in ethanol were performed. At each step of the loading process, the pore filling was characterized by nitrogen adsorption experiments and by X-ray diffraction. The impregnation procedure results in a significant improvement of the amount of ibuprofen loaded into MCM 41. The in vitro drug release was investigated with simulated biological fluids (gastric and intestinal). Hundred percent release is observed at the end of the in vitro experiment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15093603     DOI: 10.1016/j.ejpb.2003.12.007

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  35 in total

1.  Comparison of oxidized porous silicon with bare porous silicon as a photothermal agent for cancer cell destruction based on in vitro cell test results.

Authors:  Chongmu Lee; Chanseok Hong; Jungkeun Lee; Mikwon Son; Soon-Sun Hong
Journal:  Lasers Med Sci       Date:  2011-12-08       Impact factor: 3.161

2.  Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum.

Authors:  Jennifer S Park; Joseph M Kinsella; Danielle D Jandial; Stephen B Howell; Michael J Sailor
Journal:  Small       Date:  2011-06-01       Impact factor: 13.281

Review 3.  Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?

Authors:  Roudayna Diab; Chiraz Jaafar-Maalej; Hatem Fessi; Philippe Maincent
Journal:  AAPS J       Date:  2012-07-06       Impact factor: 4.009

4.  Novel/conceptual floating pulsatile system using high internal phase emulsion based porous material intended for chronotherapy.

Authors:  Praveen Sher; Ganesh Ingavle; Surendra Ponrathnam; James R Benson; Nai-Hong Li; Atmaram P Pawar
Journal:  AAPS PharmSciTech       Date:  2009-11-20       Impact factor: 3.246

5.  Development of duloxetine hydrochloride loaded mesoporous silica nanoparticles: characterizations and in vitro evaluation.

Authors:  Mani Ganesh; Udhumansha Ubaidulla; Pushparaj Hemalatha; Mei Mei Peng; Hyun Tae Jang
Journal:  AAPS PharmSciTech       Date:  2015-01-22       Impact factor: 3.246

6.  β-TCP porous pellets as an orthopaedic drug delivery system: ibuprofen/carrier physicochemical interactions.

Authors:  Hiba Baradari; Chantal Damia; Maggy Dutreih-Colas; Eric Champion; Dominique Chulia; Marylène Viana
Journal:  Sci Technol Adv Mater       Date:  2011-09-29       Impact factor: 8.090

7.  Pharmacological activity of ibuprofen released from mesoporous silica.

Authors:  Y Lang; D P Finn; A Pandit; P J Walsh
Journal:  J Mater Sci Mater Med       Date:  2011-11-22       Impact factor: 3.896

8.  Porous silicon confers bioactivity to polycaprolactone composites in vitro.

Authors:  J R Henstock; U R Ruktanonchai; L T Canham; S I Anderson
Journal:  J Mater Sci Mater Med       Date:  2014-01-08       Impact factor: 3.896

9.  Porous carriers for controlled/modulated drug delivery.

Authors:  G Ahuja; K Pathak
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

Review 10.  Porous silicon in drug delivery devices and materials.

Authors:  Emily J Anglin; Lingyun Cheng; William R Freeman; Michael J Sailor
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.